The evolution of MDM2 family genes

被引:37
作者
Momand, Jamil [1 ]
Villegas, Alberto [1 ]
Belyi, Vladimir A. [2 ,3 ]
机构
[1] Calif State Univ Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90032 USA
[2] Inst Adv Study, Princeton, NJ 08540 USA
[3] Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ 08901 USA
关键词
Cancer; MDM; MDM2; MDM4; MDMX; p53; P53; PATHWAY; PROTEIN; RING; ONCOPROTEIN; GENOME; EXPRESSION; LIGASE; DOMAIN; ARF; OLIGOMERIZATION;
D O I
10.1016/j.gene.2011.06.030
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
MDM2 and MDM4 are proto-oncoproteins that bind to and inhibit members of the p53 protein family, p53, p73 and possibly p63. p53 is a mammalian tumor suppressor and p63 and p73 are critical for development. With the sequencing of genomes from multiple organisms there is mounting evidence for a consensus scenario of p53 gene family evolution. A single p53/p63/p73 gene is in invertebrates and required for maintenance of germline DNA. Gene duplication occurred in an ancestor in common with cartilaginous fishes, giving rise to a separate p53 gene and at least one ancestral p63/p73 gene. In bony vertebrates, all three p53 gene family paralogs, p53, p63, and p73 are distinct genes. This raises the question of how MDM2 and MDM4 genes evolved. We show evidence that MDM2 and MDM4 arose from a gene duplication event prior to the emergence of bony vertebrates more than 440 million years ago. Comparative genome studies indicate that invertebrate organisms have only one MDM homolog. In jawed vertebrates, the p53-binding domains of MDM2 and MDM4 proteins evolved at a high rate, approaching the evolution rate of the MDM2-binding domain of p53. However, the MDM2-binding domain of p73 exhibits markedly stronger conservation suggesting novel p53-independent functions. The most conserved domain within all MDM2 family members is the RING domain of the MDM2 ortholog which is responsible for ubiquitination of p53 and heterodimerization with MDM4. We suggest a model where oligomerization is an ancient function of MDM and ubiquitination activity was acquired later near the MDM gene duplication event coinciding with the time of the emergence of p53 as a distinct gene. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 50 条
  • [21] Dihydropyrimidine derivatives as MDM2 inhibitors
    Mehri, Ali
    Mahnam, Karim
    Sirous, Hajar
    Aghaei, Mahmoud
    Rafiei, Leila
    Rostami, Mahboubeh
    CHEMICAL BIOLOGY & DRUG DESIGN, 2024, 103 (01)
  • [22] TRIAD1 is negatively regulated by the MDM2 E3 ligase
    Bae, Seunghee
    Jung, Jin Hyuk
    An, In-Sook
    Kim, Ok-Yeoun
    Lee, Myoung Joo
    Lee, Jae Ho
    Park, In-Chul
    Lee, Su-Jae
    An, Sungkwan
    ONCOLOGY REPORTS, 2012, 28 (05) : 1924 - 1928
  • [23] Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress
    Singh, Ravi K.
    Tapia-Santos, Aixa
    Bebee, Thomas W.
    Chandler, Dawn S.
    EXPERIMENTAL CELL RESEARCH, 2009, 315 (19) : 3419 - 3432
  • [24] Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present)
    Zak, Krzysztof
    Pecak, Aleksandra
    Rys, Barbara
    Wladyka, Benedykt
    Doemling, Alexander
    Weber, Lutz
    Holak, Tad A.
    Dubin, Grzegorz
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (04) : 425 - 448
  • [25] Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
    Huun, Johanna
    Gansmo, Liv B.
    Mannsaker, Bard
    Iversen, Gjertrud Titlestad
    Ovrebo, Jan Inge
    Lonning, Per E.
    Knappskog, Stian
    BMC CELL BIOLOGY, 2017, 18
  • [26] Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs
    Draganov, Alexander B.
    Yang, Xiaoxiao
    Anifowose, Abiodun
    De La Cruz, Ladie Kimberly C.
    Dai, Chaofeng
    Ni, Nanting
    Chen, Weixuan
    De Los Santos, Zeus
    Gu, Lubing
    Zhou, Muxiang
    Wang, Binghe
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (17) : 3860 - 3865
  • [27] Design of a novel MDM2 binding peptide based on the p53 family
    Arumugam, Madhumalar
    Jun, Lee Hui
    Brown, Christopher J.
    Lane, David
    Verma, Chandra
    CELL CYCLE, 2009, 8 (17) : 2828 - 2836
  • [28] Clinical Overview of MDM2/X-Targeted Therapies
    Burgess, Andrew
    Chia, Kee Ming
    Haupt, Sue
    Thomas, David
    Haupt, Ygal
    Lim, Elgene
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [29] Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2
    Vogel, Simon M.
    Bauer, Matthias R.
    Joerger, Andreas C.
    Wilcken, Rainer
    Brandt, Tobias
    Veprintsev, Dmitry B.
    Rutherford, Trevor J.
    Fersht, Alan R.
    Boeckler, Frank M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (42) : 16906 - 16910
  • [30] Analysis of MDM2 and TP53 genes in canine liposarcoma
    Muscatello, Luisa Vera
    de Biase, Dario
    Maloberti, Thais
    di Oto, Enrico
    Tallini, Giovanni
    Pellegrino, Valeria
    Bacci, Barbara
    Roccabianca, Paola
    Lepri, Elvio
    Crippa, Luca
    Avallone, Giancarlo
    SCIENTIFIC REPORTS, 2024, 14 (01):